EP 0951564 A1 19991027 - METHOD FOR THE DETECTION OF COMPOUNDS THAT MODULATE THE EFFECTS OF THE OBESE (OB) PROTEIN
Title (en)
METHOD FOR THE DETECTION OF COMPOUNDS THAT MODULATE THE EFFECTS OF THE OBESE (OB) PROTEIN
Title (de)
VERFAHREN ZUM NACHWEIS ZUR MODULATION DER EFFEKTE VOM OBESITÄTS-(OB)-PROTEIN
Title (fr)
PROCEDE POUR LA DETECTION DE COMPOSES MODULANT LES EFFETS DE LA PROTEINE DE L'OBESITE (OB)
Publication
Application
Priority
- GB 9702988 W 19971030
- GB 9622866 A 19961101
- GB 9622867 A 19961101
- GB 9622865 A 19961101
- GB 9622869 A 19961101
- GB 9622847 A 19961101
- GB 9622849 A 19961101
- GB 9622851 A 19961101
- GB 9622870 A 19961101
- GB 9622868 A 19961101
- GB 9622848 A 19961101
- GB 9622850 A 19961101
Abstract (en)
[origin: WO9820158A1] A method for the detection of a compound that mimics, potentiates or inhibits the physiological effect of the ob-protein, which method comprises: (a) for a compound which mimics the physiological effect of the ob-protein, assessing the effect of the compound upon an ob-protein activated signal transducer and activator of transcription (STAT) DNA response element coupled to a reporter gene; or (b) for a compound which potentiates or inhibits the physiological effect of the ob-protein, assessing the effect of the compound upon the response provided by ob-protein upon an ob-protein activated STAT DNA response element coupled to a reporter gene; wherein, the response element and the reporter being expressed in an ob-protein responsive cell line, which cell line is selected from the list consisting of: a hypothalamic derived cell line; a pheochromocytoma derived cell line; a haematopoietic derived cell line; a pancreatic derived cell line; a liver derived cell line; a preadipocyte derived cell line; a skeletal muscle derived cell line; and an ovarian derived cell line; or the response element and the reporter are expressed in a cell line, which cell line (the engineered cell line) is also transfected with a polypeptide which is capable of mediating the stimulation by ob-protein of an ob-protein activated STAT DNA response element and contains the appropriate STAT proteins.
IPC 1-7
IPC 8 full level
G01N 33/50 (2006.01); C07K 14/575 (2006.01); C07K 14/72 (2006.01); C12N 15/00 (2006.01); C12Q 1/68 (2006.01); G01N 33/15 (2006.01)
CPC (source: EP KR)
C07K 14/5759 (2013.01 - EP); C07K 14/72 (2013.01 - EP); C12Q 1/68 (2013.01 - KR); C12Q 1/6897 (2013.01 - EP)
Citation (examination)
- WO 9528482 A2 19951026 - LIGAND PHARM INC [US]
- PNAS, vol. 93, June 1996, pg.: 6221-6224
- FEBS, vol. 373, 1995, pg.: 13-18
- Nature Genetics, vol. 14, September 1996, pg.: 95-97
- See also references of WO 9820158A1
Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9820158 A1 19980514; AR 010262 A1 20000607; AU 4789297 A 19980529; CA 2270431 A1 19980514; CZ 149999 A3 19991013; EP 0951564 A1 19991027; IL 129685 A0 20000229; JP 2001503982 A 20010327; KR 20000053007 A 20000825; NO 992107 D0 19990430; NO 992107 L 19990630; NZ 335489 A 20010126; PL 333187 A1 19991122; TR 199900963 T2 19990823
DOCDB simple family (application)
GB 9702988 W 19971030; AR P970105064 A 19971031; AU 4789297 A 19971030; CA 2270431 A 19971030; CZ 149999 A 19971030; EP 97910545 A 19971030; IL 12968597 A 19971030; JP 52112898 A 19971030; KR 19997003890 A 19990501; NO 992107 A 19990430; NZ 33548997 A 19971030; PL 33318797 A 19971030; TR 9900963 T 19971030